What is Zymeworks's stock-based comp?

Zymeworks (ZYME) reported stock-based comp of $6.94M in Q1 2026.

How has Zymeworks's stock-based comp changed year-over-year?

Zymeworks's stock-based comp increased by 8.3% year-over-year, from $6.4M to $6.94M.

What is the long-term trend for Zymeworks's stock-based comp?

Over 3 years (2021 to 2025), Zymeworks's stock-based comp has grown at a 37.6% compound annual growth rate (CAGR), from $10.76M to $28.03M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Zymeworks ZYME Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

AmgenAMGN

$75M-11.8%

AnaptysBio, Inc.ANAB

$14.22M+55.0%

Viridian Therapeutics, Inc.VRDN

$13.39M+31.0%

AbCellera Biologics Inc.ABCL

$12.01M-18.8%

Stoke Therapeutics, Inc.STOK

$8.75M+29.6%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's stock-based comp?: Zymeworks (ZYME) reported stock-based comp of $6.94M in Q1 2026.
How has Zymeworks's stock-based comp changed year-over-year?: Zymeworks's stock-based comp increased by 8.3% year-over-year, from $6.4M to $6.94M.
What is the long-term trend for Zymeworks's stock-based comp?: Over 3 years (2021 to 2025), Zymeworks's stock-based comp has grown at a 37.6% compound annual growth rate (CAGR), from $10.76M to $28.03M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.